Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist
Keywords: APO, apomorphine; DOI, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane; rCMRglc, regional cerebral metabolic rates for glucose; SSRI, selective serotonin reuptake inhibitor; [14C]DG, [14C]-2-deoxy-d-glucose; 5-HT, serotonin; 8-OH-DPAT, 8-hydroxy-2(di-N-prop